Efficacy and Safety of Cilostazol for the Indication of CSPS

Completed

• Conditions: Cerebral Infarction

• Registration Number: NCT00216749
• Lead Sponsor: Korea Otsuka Pharmaceutical Co., Ltd.

Brief Summary

This is a multicenter, open-label, prospective study of cilostazol use for prevention of recurrence in patients with cerebral infarction.

Detailed Description

This is a multicenter, open-label, prospective study of cilostazol use to prevention of recurrence in patients with cerebral infarction.

Qualified patients will be treated with cilostazol by physician's assessment. This study will be continued for 4 years. More than 600 patients for 4 years.

Study Timeline

• Study Start: 2003-12
• Study First Submitted: 2005-09-14
• Study First Submitted QC: 2005-09-14
• Study First Posted: 2005-09-22
• Primary Completion: 2007-10
• Study Completion: 2007-10
• Status Verified: 2009-12
• Last Update Submitted: 2009-12-15
• Last Update Posted: 2009-12-17

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 650

Inclusion Criteria

• Patient with an experience of cerebral infarction and having a purpose for prevention of recurrence of cerebral infarction.
• Age: more than 18 years of age

Exclusion Criteria

• Unqualified patients judged by study investigator(s)

Study & Design

• Study Type: OBSERVATIONAL
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
1)Efficacy:Recurrence of cerebral infarction 2)Safety:Adverse Event	3M

Trial Locations

Locations (1)

Asan Medical Center; 🇰🇷 Seoul, Korea, Republic of